Back

Cholesterol metabolism and the role of PCSK9

26 August 2017 (11:22 - 11:45)
Organised by:
Congress Presentation Part of: PCSK9 inhibition - cholesterol reduction and beyond Lipids (Epidemiology and Prevention) ESC Premium Access ESC Congress 2017

About the speaker

Photo
Professor Stephen Nicholls

Monash University, Melbourne (Australia)

3 More presentations in this session

Presentation thumbnail
A global view: the rationale for aggresive LDL lowering
Professor S. Nissen (Cleveland, US)
Slides Video
Presentation thumbnail
Show me the data: clinical efficacy, safety and indications of PCSK9 inhibition
Professor J. Jukema (Leiden, NL)
Slides Video
Presentation thumbnail
Are there effects of PCSK9 inhibitors beyond cholesterol lowering?
Professor B. Cariou (Nantes, FR)
Slides Video

Access the full session

Session thumbnail
PCSK9 inhibition - cholesterol reduction and beyond

The Event

Event poster

ESC Congress 2017

26 August 2017 11:22 CET
You may be interested in
thumbnail
Congress Presentation
Efficacy and safety of proprotein covertase subtilisin/kexin type 9 inhibitors among patients with acute coronary syndrome: a meta-analysis of randomized controlled trials
27 August 2022
thumbnail
Congress Session
Optimising cholesterol levels through dietary interventions: key strategies and evidence
23 June 2023
thumbnail
Congress Presentation
Role of the gut microbiome for the cholesterol lowering effect of atorvastatin
31 August 2019
thumbnail
Congress Presentation
Epigenetic regulation of PCSK9 expression by statins
26 August 2023

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources